Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154143" target="_blank" >RIV/61989592:15110/15:33154143 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.jmoldx.2015.03.007" target="_blank" >http://dx.doi.org/10.1016/j.jmoldx.2015.03.007</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jmoldx.2015.03.007" target="_blank" >10.1016/j.jmoldx.2015.03.007</a>

Result language
angličtina
Original language name
Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR
Original language description
Administration of drugs targeting HERZ (official symbol ERBB2) is an important component of therapy for breast cancer patients with HER2 amplification/overexpression as determined by in situ hybridization (ISH) and immunohistochemistry (IHC).
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Result description